The Medicines Company has acquired German-based Curacyte Discovery GmbH and its lead compound, CU-2010, which is being developed for the prevention of surgical blood loss.
CU-2010 is a small molecule serine protease inhibitor. In preclinical studies, the compound has demonstrated a favourable pharmacokinetic profile for the surgical setting with a rapid onset and offset of effect, due to its short half life. The molecule was designed and is being developed to address a significant unmet medical need that has intensified for clinicians since the recent withdrawal of aprotinin.
The Medicines Company expects to commence Phase I clinical testing of CU-2010 in 2008. This acquisition gives The Medicines Company an integrated development capability around inhibitors of serine proteases - a drug class that includes bivalirudin (Angiomax), the Company's leading hospital antithrombotic.
"The acquisition of CU-2010 fits within our focused business development strategy--which is to evaluate both early- and late-stage compounds in our core area of expertise, critical care medicine, particularly thrombosis and haemostasis," stated Glenn Sblendorio, Executive Vice President and Chief Financial Officer of The Medicines Company. "CU-2010 brings further depth into our existing portfolio of marketed and development products in cardiac critical care."
The Medicines Company continues to focus on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.
"We are transitioning to a company with multiple sources of revenue. Angiomax continues to grow in the United States; we anticipate increased uptake in Europe in 2009 based on new labeling and trials data; and with the approval of Cleviprex in the U.S., we have strengthened our outlook considerably. We further anticipate completion of worldwide Phase III trials of cangrelor in 2009 and the addition of CU-2010 and other compounds to the development pipeline, provides more long term growth potential" said Clive Meanwell, M.D., CEO. "We are also pleased to demonstrate our commitment to investments in medical science in Germany - one of the world's most innovative and important hospital critical care markets - where Angiox and our other compounds can establish our presence strongly."
The Medicines Company paid EUR 14.5 million upon signing of the agreement. On decision by The Medicines Company to progress development of CU-2010 into Phase II, a further payment of EUR 10.5 million will be made. If commercialized, a low, single-digit royalty and a single future commercial milestone will be made.
The Medicines Company plans to announce third quarter 2008 financial results in October. At that time, the Company will provide an update on expected 2008 full-year expenses and net income based upon completion of the valuation of the transaction and transition costs.
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The company markets Angiomax (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, as well as Cleviprex (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable.
Curacyte Discovery GmbH, is a wholly-owned subsidiary of Curacyte AG. Curacyte AG is an advanced biopharmaceutical company dedicated to the development of new therapeutics for acute and critical care conditions.